New scan could spot prostate cancer earlier and more accurately

NCT ID NCT05422105

Terminated Diagnosis Sponsor: Primo Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial evaluates a new imaging technique called 18F-PSMA-1007 PET/CT for detecting prostate cancer in men with elevated PSA levels (4-20 ng/mL) or abnormal rectal exams. The scan uses a radioactive tracer that targets a protein common on prostate cancer cells, aiming to improve accuracy over standard tests. About 230 men receiving their first prostate biopsy will be scanned to see how well this method identifies cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-PSMA-1007
What this could lead to: If successful, this imaging method could become a more accurate, non-invasive way to detect early prostate cancer, reducing unnecessary biopsies.
What could go wrong: This is a diagnostic accuracy study, not a treatment trial. The scan may still miss some cancers or give false alarms, and results need confirmation in larger, diverse populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER PROSTATE NEOPLASM

Contacts and locations

Show contact details

Locations

Shin Kong Wu Ho-Su Memorial Hospital

Taipei, 111, Taiwan
Tungs'Taichung Metro Harbor Hospital

Taichung, 43503, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.